Announced a 1-for-25 reverse stock split, which typically signals financial distress and dilutes shareholder value, causing a sharp price decline.
Impact on stocks 1
Biotech & Genomic Medicine
PFSA
▼ NegativeCapitalrelevance
Profusa announced a 1-for-25 reverse stock split, sending shares down 28.08% to $0.09 on Thursday and a further 3.85% to $0.08 in overnight trading. The split takes effect at 12:01 am Eastern Time on July 7, 2026, with shares trading on a post-split basis on Nasdaq under the existing ticker PFSA but a new CUSIP number. Every 25 shares will be consolidated into one, reducing outstanding shares from approximately 13.2 million to about 0.53 million, while authorized shares remain at 601 million and the par value stays at $0.0001 per share. The stock has traded between $0.08 and $412.50 over the past year.
Announced a 1-for-25 reverse stock split, which typically signals financial distress and dilutes shareholder value, causing a sharp price decline.